Administration of the multikinase inhibitor NVP-AST487 (an inhibitor of FLT3 which additionally inhibits RET, KDR, c-KIT and c-ABL at high concentrations) reduced tumor volume, corresponding to downregulation of MAPK, PI3K, and STAT1/3 [5]. Here, ABL1 is linked to neoplasm.